This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).

This handbook provides guidance on using the web-based, multimedia tool Decisions in Recovery: Medications for Opioid Addiction. This handbook and the web-based tool offers information about medication-assisted treatment. Both resources help people living with opioid use disorder compare treatment options and discuss their preferences with a provider.

This guide explains prescription drug monitoring programs (PDMPs), and how they can enhance clinical decision making. The guide also explains how PDMP improves patient safety, while helping to decrease prescription drug misuse and unintentional overdose deaths.

This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.

This advisory answers questions about the seriousness of prescription drug misuse. It explains how people become dependent on prescription drugs, and treatment options. The advisory also offers necessary treatment resources for professionals.